190 related articles for article (PubMed ID: 34397194)
1. Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone.
Hsu E; Eton O; Patel AV; Cartun R; Earle JS; Mnayer LO; Kotowitz J; Yu PP
J Drugs Dermatol; 2021 Aug; 20(8):901-904. PubMed ID: 34397194
[TBL] [Abstract][Full Text] [Related]
2. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
3. PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Rischin D; Spigel DR; Adkins D; Wein R; Arnold S; Singhal N; Lee O; Murugappan S
Head Neck; 2016 Apr; 38 Suppl 1():E1756-61. PubMed ID: 26681429
[TBL] [Abstract][Full Text] [Related]
4. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
5. Favorable efficacy of S-1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region.
Izumi T; Teramoto Y; Kamimura A; Doi R; Takai S; Mori T; Koizumi S; Kawahara Y; Aitake U; Lei X; Inomata N; Inafuku K; Nakamura Y
J Dermatol; 2024 Feb; 51(2):271-279. PubMed ID: 38009848
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.
Ferris RL; Geiger JL; Trivedi S; Schmitt NC; Heron DE; Johnson JT; Kim S; Duvvuri U; Clump DA; Bauman JE; Ohr JP; Gooding WE; Argiris A
Ann Oncol; 2016 Dec; 27(12):2257-2262. PubMed ID: 27733374
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
Del Barco Morillo E; Mesía R; Adansa Klain JC; Vázquez Fernández S; Martínez-Galán J; Pastor Borgoñon M; González-Rivas C; Caballero Daroqui J; Berrocal A; Martínez-Trufero J; Vera R; Cruz-Hernández JJ;
Oral Oncol; 2016 Nov; 62():54-59. PubMed ID: 27865372
[TBL] [Abstract][Full Text] [Related]
11. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
[TBL] [Abstract][Full Text] [Related]
13. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma.
Hourbeigt K; Ehret M; Visseaux L; Durlach A; Petit A; Sanchez J; Grange-Prunier A; Barbe C; Servagi-Vernat S; Grange F
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2789-2794. PubMed ID: 32294281
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment of advanced cutaneous squamous-cell carcinoma.
Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.
Foote MC; McGrath M; Guminski A; Hughes BGM; Meakin J; Thomson D; Zarate D; Simpson F; Porceddu SV
Ann Oncol; 2014 Oct; 25(10):2047-2052. PubMed ID: 25091317
[TBL] [Abstract][Full Text] [Related]
19. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy.
Fujimura T; Kambayashi Y; Tono H; Lyu C; Ohuchi K; Hashimoto A; Aiba S
Dermatol Ther; 2020 Jul; 33(4):e13672. PubMed ID: 32449226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]